Lithium orotate

updated

Lithium orotate is a lithium salt sold as a supplement to protect the aging brain, and it is not the salt in prescription lithium, which is lithium carbonate, FDA-labeled for bipolar I disorder. Randomized trials of low-dose lithium in mild cognitive impairment used lithium carbonate or an unstated salt, and a PubMed search on 11 October 2026 found 22 records on lithium orotate, none a randomized trial in people. Salt weight is not elemental lithium: a case report gives 3.83 mg of lithium per 100 mg of orotate versus 18.8 mg per 100 mg of carbonate.

Lithium salt, promoted for low-dose brain protection

  • A toxicology case report gives 3.83 mg of elemental lithium per 100 mg of lithium orotate versus 18.8 mg per 100 mg of lithium carbonate, so a dose must say whether it is salt weight or elemental lithium.
  • Lithium carbonate, not orotate, is FDA-labeled for bipolar I disorder in patients 7 years and older, with a boxed warning for lithium toxicity.
  • In a 2026 US pilot of 83 adults with mild cognitive impairment, low-dose lithium carbonate for 2 years met none of the 6 prespecified coprimary outcomes.
  • In a 2025 Nature paper, lithium orotate prevented amyloid and tau pathology and memory loss in Alzheimer mouse models and ageing mice; the abstract does not state the dose.
  • In 9 healthy men taking 5 mg of lithium orotate daily, 7Li-MRI detected brain lithium; the abstract does not say whether 5 mg is salt weight or elemental lithium.
  • A PubMed search on 11 October 2026 returned 22 records on lithium orotate, and none was a randomized controlled trial in people.

What is lithium orotate, and how is it different from prescription lithium?

Lithium orotate is a lithium salt sold as a supplement, while prescription lithium is lithium carbonate, FDA-labeled for bipolar I disorder in patients 7 years and older and not for brain aging. On 11 October 2026, Drugs@FDA and DailyMed searches found no lithium orotate drug or label.

Lithium orotate (PubChem CID 23686432, C5H3LiN2O4, 162.1 g/mol, CAS 5266-20-6) is a lithium salt sold as a supplement. Prescription lithium is lithium carbonate (CID 11125, CLi2O3, 73.9 g/mol, CAS 554-13-2), a different salt.

The lithium carbonate label (effective 16 August 2026; openFDA lists NDA 018558, Hikma, with an original approval status date of 29 January 1982, plus many generic applications) is indicated as monotherapy for bipolar I disorder: acute manic and mixed episodes and maintenance, in patients 7 years and older. It carries a boxed warning for lithium toxicity. It does not cover brain aging, and it does not cover lithium orotate.

On 11 October 2026, an openFDA Drugs@FDA query for lithium orotate returned no match and a DailyMed drug-name search returned no labels, so no FDA-approved lithium orotate drug was found in those two sources. Its dietary-supplement status is not established here.

PubChem: lithium orotate versus lithium carbonate; salt weight is not elemental lithium

Chemical identity record

National Library of Medicine. PubChem compound records CID 23686432 (lithium orotate) and CID 11125 (lithium carbonate). openFDA Drugs@FDA and DailyMed drug-name searches for lithium orotate run on 11 October 2026. The elemental-lithium figures come from a toxicology case report (Pauze 2007, PMID 18072162), and the supplement survey is Strawbridge 2025 (PMID 40152059).

Lithium orotate: PubChem CID 23686432, C5H3LiN2O4, 162.1 g/mol, CAS 5266-20-6. Lithium carbonate, the salt in prescription lithium: CID 11125, CLi2O3, 73.9 g/mol, CAS 554-13-2. The salt weight and the lithium weight differ a lot: a toxicology case report gives 3.83 mg of elemental lithium per 100 mg of lithium orotate versus 18.8 mg per 100 mg of lithium carbonate, so a label dose written as 5 mg or 120 mg needs to say whether it is salt or elemental lithium. Lithium supplements are also sold as other salts: in a survey of 211 supplement users the most common form was aspartate at 10 mg once a day. On 11 October 2026 an openFDA Drugs@FDA query for lithium orotate returned no match and a DailyMed drug-name search returned no labels.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined salts; supplement product forms vary
Follow-up
Searches run on 11 October 2026
Study design
NLM chemical records plus dated US approval-record search
Funding
not stated in the source

Identity records and a search only; they say nothing about efficacy or safety. Whether common retail orotate products list salt weight or elemental lithium is not established here, and the US dietary-supplement status of lithium orotate is not established here.

Read the original source
Lithium carbonate label, version effective 16 August 2026: bipolar I disorder, boxed warning for lithium toxicity

FDA prescribing information

DailyMed, U.S. National Library of Medicine. Lithium carbonate tablets and capsules, prescribing information, label version effective 16 August 2026. Set ID b839ff4b-f62d-41ab-a823-550a756d58ec. openFDA lists NDA 018558 (Hikma) with an original approval status date of 29 January 1982, plus many generic applications.

The label is indicated as monotherapy for bipolar I disorder: acute manic and mixed episodes and maintenance, in patients 7 years and older. It carries a boxed warning for lithium toxicity, saying toxicity tracks serum lithium concentrations and can occur at doses close to therapeutic concentrations. Toxic concentrations (1.5 mEq/L or more) sit close to the therapeutic range (0.8 to 1.2 mEq/L), and above 3 mEq/L patients may progress to seizures, coma and irreversible brain damage. Warnings include diminished renal concentrating ability and nephrogenic diabetes insipidus, hyponatremia, hypothyroidism and hyperthyroidism, and hypercalcemia and hyperparathyroidism; geriatric patients may show toxicity at serum concentrations ordinarily tolerated by others.

Participants / model
Adults and children 7 and older with bipolar I disorder
Treatment
Lithium carbonate tablets and capsules
Follow-up
Label version effective 16 August 2026
Study design
FDA prescribing information
Funding
not stated in the source

This is the carbonate label. It does not cover lithium orotate, brain aging or supplements.

Read the original source

How much lithium is in a lithium orotate dose?

It depends on whether the number is salt weight or elemental lithium, and the two differ a lot. A toxicology case report gives 3.83 mg of elemental lithium per 100 mg of lithium orotate versus 18.8 mg per 100 mg of lithium carbonate, so a dose written as 5 mg or 120 mg needs to say which it states.

Lithium orotate and lithium carbonate carry very different amounts of lithium per unit of salt. A toxicology case report gives 3.83 mg of elemental lithium per 100 mg of lithium orotate versus 18.8 mg per 100 mg of lithium carbonate.

So a dose written as 5 mg or 120 mg needs to say whether it is salt weight or elemental lithium. The abstract of the 9-man imaging study (5 mg daily) does not say which it is, the overdose case describes tablets listed as 120 mg lithium orotate each, and the rat doses of 100, 200 and 400 mg/kg/day are given as lithium orotate. Whether common retail orotate products list salt weight or elemental lithium is not established here.

Lithium supplements are also sold as other salts: in a survey of 211 supplement users the most common form was aspartate at 10 mg once a day, with orotate also common.

Study doses on this page are quoted as the sources state them. They are not conversions, and none should be read as an amount of lithium unless the text says elemental.

PubChem: lithium orotate versus lithium carbonate; salt weight is not elemental lithium

Chemical identity record

National Library of Medicine. PubChem compound records CID 23686432 (lithium orotate) and CID 11125 (lithium carbonate). openFDA Drugs@FDA and DailyMed drug-name searches for lithium orotate run on 11 October 2026. The elemental-lithium figures come from a toxicology case report (Pauze 2007, PMID 18072162), and the supplement survey is Strawbridge 2025 (PMID 40152059).

Lithium orotate: PubChem CID 23686432, C5H3LiN2O4, 162.1 g/mol, CAS 5266-20-6. Lithium carbonate, the salt in prescription lithium: CID 11125, CLi2O3, 73.9 g/mol, CAS 554-13-2. The salt weight and the lithium weight differ a lot: a toxicology case report gives 3.83 mg of elemental lithium per 100 mg of lithium orotate versus 18.8 mg per 100 mg of lithium carbonate, so a label dose written as 5 mg or 120 mg needs to say whether it is salt or elemental lithium. Lithium supplements are also sold as other salts: in a survey of 211 supplement users the most common form was aspartate at 10 mg once a day. On 11 October 2026 an openFDA Drugs@FDA query for lithium orotate returned no match and a DailyMed drug-name search returned no labels.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined salts; supplement product forms vary
Follow-up
Searches run on 11 October 2026
Study design
NLM chemical records plus dated US approval-record search
Funding
not stated in the source

Identity records and a search only; they say nothing about efficacy or safety. Whether common retail orotate products list salt weight or elemental lithium is not established here, and the US dietary-supplement status of lithium orotate is not established here.

Read the original source
Orotate in people: a 9-man imaging study, a 1986 uncontrolled report, one case, one registered trial

Human study

Neal MA et al. J Affect Disord. 2024;360:139-145. PMID 38810780.

Nine healthy men took lithium orotate supplements at 5 mg daily for up to 28 days and 7Li-MRI on a 3T scanner detected brain lithium, with two participants showing about 2 to 4 times higher signal; adherence was self-reported, and the abstract does not say whether 5 mg is salt weight or elemental lithium. A 1986 uncontrolled report of 42 alcoholic patients given 150 mg of lithium orotate daily within a multi-component program described minor side effects, and cannot separate lithium orotate from the other treatments. In one Dutch case report a woman taking an internet lithium orotate supplement had a serum lithium below 0.05 mmol/l. The only registered orotate trial found is NCT07459959 (Johns Hopkins University, lithium orotate versus placebo in early Alzheimer disease, estimated 40 participants, phase 1/2, not yet recruiting, listed start 1 December 2026, primary outcomes feasibility, safety and tolerability, no results).

Participants / model
9 healthy men; 42 alcoholic patients; one case report; a registered early Alzheimer disease trial
Treatment
Oral lithium orotate 5 mg or 150 mg daily as stated; an internet supplement
Follow-up
Up to 28 days; not stated in the source for the other reports
Study design
Small imaging study, uncontrolled report, case report and trial registry
Funding
not stated in the source

None of these tests efficacy. The 5 mg and 150 mg figures are as stated in the sources, and the abstract of the 9-man study does not say whether 5 mg is salt weight or elemental lithium.

Read the original source
Orotate safety: rat NOAEL 400 mg/kg/day (independence unclear), one overdose case, a survey of 211 users

Animal study

Murbach TS et al. Regul Toxicol Pharmacol. 2021;124:104973. PMID 34146638.

In rats given lithium orotate 100, 200 or 400 mg/kg/day for 28 days, no toxicity or target organs were found (NOAEL 400 mg/kg/day), and genotoxicity tests were negative; the paper states that therapeutic lithium doses are 5.5 to 67 times greater than typically recommended supplemental lithium orotate. An 18-year-old who swallowed 18 tablets of an internet lithium orotate supplement (listed as 120 mg lithium orotate each) had a serum lithium of 0.31 then 0.40 mEq/L with nausea, one emesis and mild tremor, and the authors note chronic toxicity is a theoretical concern (Pauze 2007). Among 211 people who took lithium supplements (mostly aspartate 10 mg, with orotate also common), side effects and withdrawal phenomena were reported as more prevalent than the authors expected, in an opportunistic cross-sectional survey (Strawbridge 2025).

Participants / model
Rats; one overdose case; 211 supplement users
Treatment
Oral lithium orotate in rats; supplement tablets; self-reported supplement use
Follow-up
28 days (rats)
Study design
Animal toxicology study, case report and cross-sectional survey
Funding
not stated in the source; the rat paper's abstract gives an AIBMR contact email and no funding or conflict statement

The rat study's independence is not established, because its abstract gives an AIBMR contact email and no funding or conflict statement.

Read the original source

What did the low-dose lithium carbonate trials and water studies find?

In small randomized trials of low-dose lithium in mild cognitive impairment, two reports from one Brazilian trial were promising and a 2026 US pilot of 83 adults met none of its 6 prespecified coprimary outcomes. These used lithium carbonate or an unstated salt, not orotate. Drinking-water lithium studies in Denmark and Scotland were mixed.

In 45 people with amnestic mild cognitive impairment (MCI) given lithium to serum concentrations of 0.25 to 0.5 mmol/l or placebo for 12 months, cerebrospinal fluid phosphorylated tau fell (P = 0.03) with better ADAS-cog and attention scores (NCT01055392). In 61 people with amnestic MCI given lithium carbonate to subtherapeutic concentrations (0.25 to 0.5 mEq/L) for 2 years, placebo participants declined while lithium participants stayed stable, and CSF amyloid-beta 1-42 rose after 36 months; the declaration of interest was none.

In a 2026 US pilot of 83 randomized adults aged 60 or older with MCI (41 lithium carbonate, 42 placebo) on low-dose lithium for 2 years, none of the 6 prespecified coprimary outcomes met the significance threshold. The CVLT-II delayed recall decline was 1.42 points a year on placebo versus 0.73 on lithium (difference 0.69; 95% CI 0.01 to 1.37; P = .05), and hippocampal and cortical volumes declined in both groups.

A microdose study of 300 ug once daily for 15 months in people with Alzheimer disease reported MMSE stable on treatment against decline in controls. Its abstract gives no sample size or lithium salt.

A Danish nationwide nested case-control study of 73 731 people with dementia and 733 653 controls found a nonlinear link with lithium in drinking water: compared with 2.0 to 5.0 ug/L, the dementia incidence rate ratio was 0.83 (95% CI 0.81 to 0.85) above 15.0 ug/L, 0.98 (0.96 to 1.01) at 10.1 to 15.0 ug/L and 1.22 (1.19 to 1.25) at 5.1 to 10.0 ug/L, and the authors say confounding by municipality cannot be excluded. A Scottish cohort of 37 597 people with a mean water lithium of 1.45 ug/L did not support a protective association and found a trend to higher dementia risk in women at levels below 2.1 ug/L (HR 1.17, 95% CI 1.04 to 1.32 in the second quartile).

All of these used lithium carbonate, an unstated salt or environmental lithium, and none used orotate. Drinking-water lithium is not an orotate supplement dose. The 2011 and 2019 reports share one registry number, and it is not stated whether the 45 are a subset of the 61.

Low-dose lithium in cognitive impairment: 45, 61 and 83 participants; the 2026 pilot met none of 6 coprimary outcomes

Randomized controlled trial

Gildengers AG et al. JAMA Neurol. 2026;83(4):310-319. PMID 41770546.

In 45 people with amnestic mild cognitive impairment (MCI) given lithium to serum concentrations of 0.25 to 0.5 mmol/l or placebo for 12 months, cerebrospinal fluid phosphorylated tau fell (P = 0.03) with better ADAS-cog and attention scores (Forlenza 2011). In 61 people with amnestic MCI given lithium carbonate to subtherapeutic concentrations (0.25 to 0.5 mEq/L) for 2 years, placebo participants declined while lithium participants stayed stable, and CSF amyloid-beta 1-42 rose after 36 months; the declaration of interest was none (Forlenza 2019). In a 2026 US pilot of 83 randomized adults aged 60 or older with MCI (41 lithium carbonate, 42 placebo) on low-dose lithium for 2 years, none of the 6 prespecified coprimary outcomes met the significance threshold; the CVLT-II delayed recall decline was 1.42 points a year on placebo versus 0.73 on lithium (difference 0.69; 95% CI 0.01 to 1.37; P = .05), and hippocampal and cortical volumes declined in both groups (Gildengers 2026). A microdose study of 300 ug once daily for 15 months in people with Alzheimer disease reported MMSE stable on treatment against decline in controls; its abstract gives no sample size or lithium salt (Nunes 2013).

Participants / model
Older adults with amnestic MCI (45, 61 and 83 participants in three reports); patients with Alzheimer disease (sample size not stated in the source)
Treatment
Oral lithium or lithium carbonate at subtherapeutic serum levels; a microdose of an unstated salt
Follow-up
12 months; 2 years; 2 years; 15 months
Study design
Randomized placebo-controlled trials and a small pilot
Funding
not stated in the source; the 2019 report declared no interest

All of these used lithium carbonate or an unstated salt, not orotate. The 2011 and 2019 reports share one registry number, and it is not stated whether the 45 are a subset of the 61.

Read the original source
Drinking-water lithium: Danish (73 731 cases) and Scottish (37 597 people) studies, mixed

Human study

Kessing LV et al. JAMA Psychiatry. 2017;74(10):1005-1010. PMID 28832877.

A Danish nationwide nested case-control study of 73 731 people with dementia and 733 653 controls found a nonlinear link: compared with 2.0 to 5.0 ug/L lithium in drinking water, the dementia incidence rate ratio was 0.83 (95% CI 0.81 to 0.85) above 15.0 ug/L, 0.98 (0.96 to 1.01) at 10.1 to 15.0 ug/L, and 1.22 (1.19 to 1.25) at 5.1 to 10.0 ug/L, and the authors say confounding by municipality cannot be excluded. A Scottish cohort of 37 597 people with a mean water lithium of 1.45 ug/L did not support a protective association and found a trend to higher dementia risk in women at levels below 2.1 ug/L (HR 1.17, 95% CI 1.04 to 1.32 in the second quartile).

Participants / model
Danish and Scottish general populations
Treatment
Environmental lithium in drinking water
Follow-up
not stated in the source
Study design
Observational nested case-control study and cohort study
Funding
not stated in the source

Drinking-water lithium is not an orotate supplement dose.

Read the original source

What is known about lithium orotate itself in people?

Very little. A 9-man imaging study detected brain lithium on 5 mg daily, a 1986 uncontrolled report in 42 alcoholic patients cannot separate orotate from other treatments, and one case report found serum lithium below 0.05 mmol/l. No randomized trial of orotate in people was found, and the only registered orotate trial is not yet recruiting.

Nine healthy men took lithium orotate supplements at 5 mg daily for up to 28 days, and 7Li-MRI on a 3T scanner detected brain lithium, with two participants showing about 2 to 4 times higher signal. Adherence was self-reported, and the abstract does not say whether 5 mg is salt weight or elemental lithium.

A 1986 uncontrolled report of 42 alcoholic patients given 150 mg of lithium orotate daily within a multi-component program described minor side effects, and it cannot separate lithium orotate from the other treatments. In one Dutch case report, a woman taking an internet lithium orotate supplement had a serum lithium below 0.05 mmol/l.

The only registered orotate trial found is NCT07459959 (Johns Hopkins University, lithium orotate versus placebo in early Alzheimer disease, an estimated 40 participants, phase 1/2, not yet recruiting, listed start 1 December 2026, primary outcomes feasibility, safety and tolerability, no results).

None of these tests whether lithium orotate works, and there is no randomized trial of orotate in people among the records found.

Orotate in people: a 9-man imaging study, a 1986 uncontrolled report, one case, one registered trial

Human study

Neal MA et al. J Affect Disord. 2024;360:139-145. PMID 38810780.

Nine healthy men took lithium orotate supplements at 5 mg daily for up to 28 days and 7Li-MRI on a 3T scanner detected brain lithium, with two participants showing about 2 to 4 times higher signal; adherence was self-reported, and the abstract does not say whether 5 mg is salt weight or elemental lithium. A 1986 uncontrolled report of 42 alcoholic patients given 150 mg of lithium orotate daily within a multi-component program described minor side effects, and cannot separate lithium orotate from the other treatments. In one Dutch case report a woman taking an internet lithium orotate supplement had a serum lithium below 0.05 mmol/l. The only registered orotate trial found is NCT07459959 (Johns Hopkins University, lithium orotate versus placebo in early Alzheimer disease, estimated 40 participants, phase 1/2, not yet recruiting, listed start 1 December 2026, primary outcomes feasibility, safety and tolerability, no results).

Participants / model
9 healthy men; 42 alcoholic patients; one case report; a registered early Alzheimer disease trial
Treatment
Oral lithium orotate 5 mg or 150 mg daily as stated; an internet supplement
Follow-up
Up to 28 days; not stated in the source for the other reports
Study design
Small imaging study, uncontrolled report, case report and trial registry
Funding
not stated in the source

None of these tests efficacy. The 5 mg and 150 mg figures are as stated in the sources, and the abstract of the 9-man study does not say whether 5 mg is salt weight or elemental lithium.

Read the original source
PubMed search, 11 October 2026: 22 records, no randomized trial of orotate in people

PubMed search record

PubMed search run on 11 October 2026: "lithium orotate". 22 records returned. ClinicalTrials.gov search for "lithium orotate" run the same day.

The search returned 22 records, and all 22 titles were reviewed. They were reviews and commentaries, rat pharmacokinetic and toxicology studies, two mouse studies, two case reports and a letter, one survey and one qualitative study, one human imaging study, two older clinical reports (Sartori 1986 and a 1973 report titled as a two-year study of clinical applications, title only reviewed) and several records only tangentially about lithium. None was a randomized controlled trial of lithium orotate in people. A ClinicalTrials.gov search for lithium orotate returned 1 study (NCT07459959). All randomized human evidence for low-dose lithium in cognitive impairment found in this review used lithium carbonate or an unstated salt.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 11 October 2026
Study design
Literature search and trial registry
Funding
not stated in the source

A search result shows what PubMed returned on that date. It is not proof that no unindexed study exists.

Read the original source

What do the mouse and rat studies say about orotate?

A 2025 Nature paper found lithium orotate prevented amyloid and tau pathology and memory loss in Alzheimer mouse models and ageing mice, and orotate outperformed carbonate at lower doses in a mouse mania model. Whether orotate behaves differently from other salts is disputed: a 1978 rat study found higher brain lithium, a 1976 study found no difference, and a 1979 repeat found lower kidney function after orotate.

A Nature paper found that, of the metals analyzed, lithium was the only one significantly reduced in the brain in people with MCI, and that amyloid sequestration lowered lithium bioavailability further in Alzheimer disease. Cutting cortical lithium by about 50% in mice worsened amyloid and tau pathology and cognition, and replacement with lithium orotate, described as a salt with reduced amyloid binding, prevented pathological changes and memory loss in Alzheimer mouse models and ageing wild-type mice. No competing interests were declared. The abstract does not state the orotate dose given to mice, so no mouse-to-human dose conversion is offered.

In a mouse mania model, lithium orotate near-completely blocked amphetamine-induced hyperlocomotion at 1.5 mg/kg while lithium carbonate partly blocked it at 15 and 20 mg/kg, and after 14 days only the carbonate caused polydipsia, raised creatinine in males and raised TSH in females. A 2026 narrative review concludes that the data support a prospective trial of low-dose lithium orotate in MCI and that the repletion hypothesis awaits independent replication.

Whether orotate behaves differently from other lithium salts is disputed. In rats, single injections of 1.0 to 4.0 mEq/kg gave higher serum and brain lithium 8 hours after lithium orotate than after lithium carbonate, with a 24-hour brain level about three times greater (Kling 1978). Smith reported in 1976 that uptake, distribution and excretion of lithium did not differ between orotate, carbonate and chloride after single doses or 20 days of feeding.

Smith and Schou repeated the Kling experiment in 1979 and found markedly lower glomerular filtration rate and urine flow after lithium orotate, with the higher lithium concentrations accounted for by the lower kidney function, and advised against using lithium orotate to treat patients. A 2026 commentary argues that no study has shown stable orotate in physiological fluids, that it should be protonated in the stomach and absorbed as Li+, that experimental studies show comparable pharmacokinetics for the two salts, and that focus on one salt could have safety implications.

Orotate in mice: a 2025 Nature paper and a mouse mania study, with no human efficacy data

Animal study

Aron L et al. Nature. 2025;645(8081):712-721. PMID 40770094.

A Nature paper found that of the metals analyzed, lithium was the only one significantly reduced in the brain in people with MCI, that amyloid sequestration lowered lithium bioavailability further in Alzheimer disease, that cutting cortical lithium by about 50% in mice worsened amyloid and tau pathology and cognition, and that replacement with lithium orotate, described as a salt with reduced amyloid binding, prevented pathological changes and memory loss in Alzheimer mouse models and ageing wild-type mice. In a mouse mania model lithium orotate near-completely blocked amphetamine-induced hyperlocomotion at 1.5 mg/kg while lithium carbonate partly blocked it at 15 and 20 mg/kg, and after 14 days only the carbonate caused polydipsia, raised creatinine in males and raised TSH in females. A 2026 narrative review concludes that the data support a prospective trial of low-dose lithium orotate in MCI and that the repletion hypothesis awaits independent replication.

Participants / model
Mice (Alzheimer models, ageing wild-type, mania model); human brain tissue measurements in MCI
Treatment
Dietary lithium depletion and lithium orotate replacement in mice; lithium orotate or carbonate in the mania model; routes and the orotate dose in the Nature paper are not stated in the source
Follow-up
14 days in the mania model; not stated in the source otherwise
Study design
Animal studies and a narrative review
Funding
No competing interests were declared in the Nature paper; funding is not stated in the source

Mouse findings only. The abstract does not state the orotate dose given to mice, so no mouse-to-human dose conversion is offered.

Read the original source
Orotate versus carbonate in rats: 1976 to 1979 papers disagree, and a 2026 commentary doubts the premise

Animal study

Kling MA et al. J Pharm Pharmacol. 1978;30(6):368-70. PMID 26768.

In rats, single injections of 1.0 to 4.0 mEq/kg gave higher serum and brain lithium 8 hours after lithium orotate than after lithium carbonate, with a 24-hour brain level about three times greater (Kling 1978). Smith reported in 1976 that uptake, distribution and excretion of lithium did not differ between orotate, carbonate and chloride after single doses or 20 days of feeding. Smith and Schou repeated the Kling experiment in 1979 and found markedly lower glomerular filtration rate and urine flow after lithium orotate, with the higher lithium concentrations accounted for by the lower kidney function, and advised against using lithium orotate to treat patients. A 2026 commentary argues that no study has shown stable orotate in physiological fluids, that it should be protonated in the stomach and absorbed as Li+, that experimental studies show comparable pharmacokinetics for the two salts, and that focus on one salt could have safety implications (Hajek 2026).

Participants / model
Rats; none in humans
Treatment
Intraperitoneal, subcutaneous, intragastric and dietary lithium salts in rats; an argument paper
Follow-up
Single doses; 20 days of feeding in one study
Study design
Animal pharmacokinetic studies from the 1970s plus a 2026 commentary
Funding
not stated in the source

Rat findings only; none in people.

Read the original source

Is lithium orotate gentler and more brain-available than prescription lithium?

Not shown in people. Low-dose lithium protecting the aging brain has small trial support for lithium carbonate and mixed population data, while the orotate-specific claim rests on mouse work and a premise that is disputed. A PubMed search on 11 October 2026 returned 22 records on lithium orotate, and none was a randomized trial in people.

Sellers say low-dose lithium, sold as lithium orotate, protects the aging brain and is gentler and more brain-available than prescription lithium. The two parts have different support. Low-dose lithium protecting the aging brain has small trial support for lithium carbonate and mixed population data. Lithium orotate being gentler and more brain-available has mouse support, no human efficacy or safety trial, and a premise that is disputed.

A PubMed search on 11 October 2026 for lithium orotate returned 22 records, and all 22 titles were reviewed. They were reviews and commentaries, rat pharmacokinetic and toxicology studies, two mouse studies, two case reports and a letter, one survey and one qualitative study, one human imaging study, two older clinical reports and several records only tangentially about lithium. None was a randomized controlled trial of lithium orotate in people.

A ClinicalTrials.gov search for lithium orotate returned 1 study (NCT07459959, not yet recruiting). All randomized human evidence for low-dose lithium in cognitive impairment found in this review, summarized above, used lithium carbonate or an unstated salt.

PubMed search, 11 October 2026: 22 records, no randomized trial of orotate in people

PubMed search record

PubMed search run on 11 October 2026: "lithium orotate". 22 records returned. ClinicalTrials.gov search for "lithium orotate" run the same day.

The search returned 22 records, and all 22 titles were reviewed. They were reviews and commentaries, rat pharmacokinetic and toxicology studies, two mouse studies, two case reports and a letter, one survey and one qualitative study, one human imaging study, two older clinical reports (Sartori 1986 and a 1973 report titled as a two-year study of clinical applications, title only reviewed) and several records only tangentially about lithium. None was a randomized controlled trial of lithium orotate in people. A ClinicalTrials.gov search for lithium orotate returned 1 study (NCT07459959). All randomized human evidence for low-dose lithium in cognitive impairment found in this review used lithium carbonate or an unstated salt.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 11 October 2026
Study design
Literature search and trial registry
Funding
not stated in the source

A search result shows what PubMed returned on that date. It is not proof that no unindexed study exists.

Read the original source
Low-dose lithium in cognitive impairment: 45, 61 and 83 participants; the 2026 pilot met none of 6 coprimary outcomes

Randomized controlled trial

Gildengers AG et al. JAMA Neurol. 2026;83(4):310-319. PMID 41770546.

In 45 people with amnestic mild cognitive impairment (MCI) given lithium to serum concentrations of 0.25 to 0.5 mmol/l or placebo for 12 months, cerebrospinal fluid phosphorylated tau fell (P = 0.03) with better ADAS-cog and attention scores (Forlenza 2011). In 61 people with amnestic MCI given lithium carbonate to subtherapeutic concentrations (0.25 to 0.5 mEq/L) for 2 years, placebo participants declined while lithium participants stayed stable, and CSF amyloid-beta 1-42 rose after 36 months; the declaration of interest was none (Forlenza 2019). In a 2026 US pilot of 83 randomized adults aged 60 or older with MCI (41 lithium carbonate, 42 placebo) on low-dose lithium for 2 years, none of the 6 prespecified coprimary outcomes met the significance threshold; the CVLT-II delayed recall decline was 1.42 points a year on placebo versus 0.73 on lithium (difference 0.69; 95% CI 0.01 to 1.37; P = .05), and hippocampal and cortical volumes declined in both groups (Gildengers 2026). A microdose study of 300 ug once daily for 15 months in people with Alzheimer disease reported MMSE stable on treatment against decline in controls; its abstract gives no sample size or lithium salt (Nunes 2013).

Participants / model
Older adults with amnestic MCI (45, 61 and 83 participants in three reports); patients with Alzheimer disease (sample size not stated in the source)
Treatment
Oral lithium or lithium carbonate at subtherapeutic serum levels; a microdose of an unstated salt
Follow-up
12 months; 2 years; 2 years; 15 months
Study design
Randomized placebo-controlled trials and a small pilot
Funding
not stated in the source; the 2019 report declared no interest

All of these used lithium carbonate or an unstated salt, not orotate. The 2011 and 2019 reports share one registry number, and it is not stated whether the 45 are a subset of the 61.

Read the original source
Orotate in mice: a 2025 Nature paper and a mouse mania study, with no human efficacy data

Animal study

Aron L et al. Nature. 2025;645(8081):712-721. PMID 40770094.

A Nature paper found that of the metals analyzed, lithium was the only one significantly reduced in the brain in people with MCI, that amyloid sequestration lowered lithium bioavailability further in Alzheimer disease, that cutting cortical lithium by about 50% in mice worsened amyloid and tau pathology and cognition, and that replacement with lithium orotate, described as a salt with reduced amyloid binding, prevented pathological changes and memory loss in Alzheimer mouse models and ageing wild-type mice. In a mouse mania model lithium orotate near-completely blocked amphetamine-induced hyperlocomotion at 1.5 mg/kg while lithium carbonate partly blocked it at 15 and 20 mg/kg, and after 14 days only the carbonate caused polydipsia, raised creatinine in males and raised TSH in females. A 2026 narrative review concludes that the data support a prospective trial of low-dose lithium orotate in MCI and that the repletion hypothesis awaits independent replication.

Participants / model
Mice (Alzheimer models, ageing wild-type, mania model); human brain tissue measurements in MCI
Treatment
Dietary lithium depletion and lithium orotate replacement in mice; lithium orotate or carbonate in the mania model; routes and the orotate dose in the Nature paper are not stated in the source
Follow-up
14 days in the mania model; not stated in the source otherwise
Study design
Animal studies and a narrative review
Funding
No competing interests were declared in the Nature paper; funding is not stated in the source

Mouse findings only. The abstract does not state the orotate dose given to mice, so no mouse-to-human dose conversion is offered.

Read the original source
Orotate versus carbonate in rats: 1976 to 1979 papers disagree, and a 2026 commentary doubts the premise

Animal study

Kling MA et al. J Pharm Pharmacol. 1978;30(6):368-70. PMID 26768.

In rats, single injections of 1.0 to 4.0 mEq/kg gave higher serum and brain lithium 8 hours after lithium orotate than after lithium carbonate, with a 24-hour brain level about three times greater (Kling 1978). Smith reported in 1976 that uptake, distribution and excretion of lithium did not differ between orotate, carbonate and chloride after single doses or 20 days of feeding. Smith and Schou repeated the Kling experiment in 1979 and found markedly lower glomerular filtration rate and urine flow after lithium orotate, with the higher lithium concentrations accounted for by the lower kidney function, and advised against using lithium orotate to treat patients. A 2026 commentary argues that no study has shown stable orotate in physiological fluids, that it should be protonated in the stomach and absorbed as Li+, that experimental studies show comparable pharmacokinetics for the two salts, and that focus on one salt could have safety implications (Hajek 2026).

Participants / model
Rats; none in humans
Treatment
Intraperitoneal, subcutaneous, intragastric and dietary lithium salts in rats; an argument paper
Follow-up
Single doses; 20 days of feeding in one study
Study design
Animal pharmacokinetic studies from the 1970s plus a 2026 commentary
Funding
not stated in the source

Rat findings only; none in people.

Read the original source

How is lithium thought to protect the brain, and does the salt matter?

A 2025 mouse paper proposes that low brain lithium worsens amyloid and tau pathology and that orotate, a salt with reduced amyloid binding, replaces it. Rat work disagrees on whether orotate delivers more lithium than carbonate, and a 2026 commentary argues orotate should be protonated in the stomach and absorbed as Li+.

The 2025 Nature paper proposes a repletion idea: lithium was the only metal significantly reduced in the brain in people with MCI, amyloid sequestration lowered lithium bioavailability further in Alzheimer disease, and replacement with lithium orotate, described as a salt with reduced amyloid binding, prevented pathology and memory loss in mice. A 2026 narrative review says the repletion hypothesis awaits independent replication.

Rat work disagrees on whether the salt matters. One 1978 study found higher serum and brain lithium after orotate than after carbonate, a 1976 study found no difference in uptake, distribution and excretion between orotate, carbonate and chloride, and a 1979 repeat found lower kidney function after orotate, with the higher lithium concentrations accounted for by the lower kidney function.

A 2026 commentary argues that orotate should be protonated in the stomach and absorbed as Li+, that experimental studies show comparable pharmacokinetics for the two salts, and that no study has shown stable orotate in physiological fluids. In people, 7Li-MRI detected brain lithium in 9 healthy men on lithium orotate supplements, but no human pharmacokinetic comparison of orotate with other salts appears in the sources reviewed.

Orotate in mice: a 2025 Nature paper and a mouse mania study, with no human efficacy data

Animal study

Aron L et al. Nature. 2025;645(8081):712-721. PMID 40770094.

A Nature paper found that of the metals analyzed, lithium was the only one significantly reduced in the brain in people with MCI, that amyloid sequestration lowered lithium bioavailability further in Alzheimer disease, that cutting cortical lithium by about 50% in mice worsened amyloid and tau pathology and cognition, and that replacement with lithium orotate, described as a salt with reduced amyloid binding, prevented pathological changes and memory loss in Alzheimer mouse models and ageing wild-type mice. In a mouse mania model lithium orotate near-completely blocked amphetamine-induced hyperlocomotion at 1.5 mg/kg while lithium carbonate partly blocked it at 15 and 20 mg/kg, and after 14 days only the carbonate caused polydipsia, raised creatinine in males and raised TSH in females. A 2026 narrative review concludes that the data support a prospective trial of low-dose lithium orotate in MCI and that the repletion hypothesis awaits independent replication.

Participants / model
Mice (Alzheimer models, ageing wild-type, mania model); human brain tissue measurements in MCI
Treatment
Dietary lithium depletion and lithium orotate replacement in mice; lithium orotate or carbonate in the mania model; routes and the orotate dose in the Nature paper are not stated in the source
Follow-up
14 days in the mania model; not stated in the source otherwise
Study design
Animal studies and a narrative review
Funding
No competing interests were declared in the Nature paper; funding is not stated in the source

Mouse findings only. The abstract does not state the orotate dose given to mice, so no mouse-to-human dose conversion is offered.

Read the original source
Orotate versus carbonate in rats: 1976 to 1979 papers disagree, and a 2026 commentary doubts the premise

Animal study

Kling MA et al. J Pharm Pharmacol. 1978;30(6):368-70. PMID 26768.

In rats, single injections of 1.0 to 4.0 mEq/kg gave higher serum and brain lithium 8 hours after lithium orotate than after lithium carbonate, with a 24-hour brain level about three times greater (Kling 1978). Smith reported in 1976 that uptake, distribution and excretion of lithium did not differ between orotate, carbonate and chloride after single doses or 20 days of feeding. Smith and Schou repeated the Kling experiment in 1979 and found markedly lower glomerular filtration rate and urine flow after lithium orotate, with the higher lithium concentrations accounted for by the lower kidney function, and advised against using lithium orotate to treat patients. A 2026 commentary argues that no study has shown stable orotate in physiological fluids, that it should be protonated in the stomach and absorbed as Li+, that experimental studies show comparable pharmacokinetics for the two salts, and that focus on one salt could have safety implications (Hajek 2026).

Participants / model
Rats; none in humans
Treatment
Intraperitoneal, subcutaneous, intragastric and dietary lithium salts in rats; an argument paper
Follow-up
Single doses; 20 days of feeding in one study
Study design
Animal pharmacokinetic studies from the 1970s plus a 2026 commentary
Funding
not stated in the source

Rat findings only; none in people.

Read the original source
Orotate in people: a 9-man imaging study, a 1986 uncontrolled report, one case, one registered trial

Human study

Neal MA et al. J Affect Disord. 2024;360:139-145. PMID 38810780.

Nine healthy men took lithium orotate supplements at 5 mg daily for up to 28 days and 7Li-MRI on a 3T scanner detected brain lithium, with two participants showing about 2 to 4 times higher signal; adherence was self-reported, and the abstract does not say whether 5 mg is salt weight or elemental lithium. A 1986 uncontrolled report of 42 alcoholic patients given 150 mg of lithium orotate daily within a multi-component program described minor side effects, and cannot separate lithium orotate from the other treatments. In one Dutch case report a woman taking an internet lithium orotate supplement had a serum lithium below 0.05 mmol/l. The only registered orotate trial found is NCT07459959 (Johns Hopkins University, lithium orotate versus placebo in early Alzheimer disease, estimated 40 participants, phase 1/2, not yet recruiting, listed start 1 December 2026, primary outcomes feasibility, safety and tolerability, no results).

Participants / model
9 healthy men; 42 alcoholic patients; one case report; a registered early Alzheimer disease trial
Treatment
Oral lithium orotate 5 mg or 150 mg daily as stated; an internet supplement
Follow-up
Up to 28 days; not stated in the source for the other reports
Study design
Small imaging study, uncontrolled report, case report and trial registry
Funding
not stated in the source

None of these tests efficacy. The 5 mg and 150 mg figures are as stated in the sources, and the abstract of the 9-man study does not say whether 5 mg is salt weight or elemental lithium.

Read the original source

What risks and unknowns come with lithium?

Prescription lithium carbonate carries a boxed warning for lithium toxicity, and chronic low-dose carbonate trials reported thyroid, weight, diabetes, arrhythmia and tolerability signals. No study found measured those for orotate: there is no safety trial of orotate in people, thyroid and renal effects of long-term orotate are unknown, and a survey of 211 supplement users reported more side effects and withdrawal phenomena than the authors expected.

The lithium carbonate label carries a boxed warning for lithium toxicity, saying toxicity tracks serum lithium concentrations and can occur at doses close to therapeutic concentrations. Toxic concentrations (1.5 mEq/L or more) sit close to the therapeutic range (0.8 to 1.2 mEq/L), and above 3 mEq/L patients may progress to seizures, coma and irreversible brain damage. Warnings include diminished renal concentrating ability and nephrogenic diabetes insipidus, hyponatremia, hypothyroidism and hyperthyroidism, and hypercalcemia and hyperparathyroidism, and geriatric patients may show toxicity at serum concentrations ordinarily tolerated by others. These are carbonate label statements, not orotate data.

In the 61-person low-dose carbonate trial followed for 2 years double-blind and 2 more single-blind, renal function by two eGFR equations did not change (P = .453 and .213), but the lithium group gained neutrophils (P = .038), serum TSH (P = .034) and body weight (P = .015), reported more adverse events overall (P = .045), and had a higher incidence of diabetes mellitus (P = .037) and arrhythmia (P = .028). The authors say other adverse events could not be ruled out given the study design. In the 2026 pilot, serious adverse events occurred in 12 of 41 (29%) on lithium versus 9 of 39 (23%) on placebo, none definitely treatment related; increased creatinine was 12 of 41 versus 12 of 39, diarrhea 12 of 41 versus 6 of 39, tiredness 12 of 41 versus 6 of 39, and tremor 10 of 41 versus 6 of 39.

For orotate itself, safety evidence is limited and partly supplier-adjacent. In rats given lithium orotate 100, 200 or 400 mg/kg/day for 28 days, no toxicity or target organs were found (NOAEL 400 mg/kg/day) and genotoxicity tests were negative, but the abstract gives an AIBMR contact email and no funding or conflict statement, so independence is not established. The paper states that therapeutic lithium doses are 5.5 to 67 times greater than typically recommended supplemental lithium orotate.

An 18-year-old who swallowed 18 tablets of an internet lithium orotate supplement (listed as 120 mg lithium orotate each) had a serum lithium of 0.31 then 0.40 mEq/L with nausea, one emesis and mild tremor, and the authors note chronic toxicity is a theoretical concern. Among 211 people who took lithium supplements (mostly aspartate 10 mg, with orotate also common), side effects and withdrawal phenomena were reported as more prevalent than the authors expected, in an opportunistic cross-sectional survey.

Thyroid and renal effects of long-term orotate in people are unknown, and the 1979 rat study found lower glomerular filtration rate and urine flow after orotate. One Dutch case report found a serum lithium below 0.05 mmol/l in a woman taking an internet orotate supplement.

Lithium carbonate label, version effective 16 August 2026: bipolar I disorder, boxed warning for lithium toxicity

FDA prescribing information

DailyMed, U.S. National Library of Medicine. Lithium carbonate tablets and capsules, prescribing information, label version effective 16 August 2026. Set ID b839ff4b-f62d-41ab-a823-550a756d58ec. openFDA lists NDA 018558 (Hikma) with an original approval status date of 29 January 1982, plus many generic applications.

The label is indicated as monotherapy for bipolar I disorder: acute manic and mixed episodes and maintenance, in patients 7 years and older. It carries a boxed warning for lithium toxicity, saying toxicity tracks serum lithium concentrations and can occur at doses close to therapeutic concentrations. Toxic concentrations (1.5 mEq/L or more) sit close to the therapeutic range (0.8 to 1.2 mEq/L), and above 3 mEq/L patients may progress to seizures, coma and irreversible brain damage. Warnings include diminished renal concentrating ability and nephrogenic diabetes insipidus, hyponatremia, hypothyroidism and hyperthyroidism, and hypercalcemia and hyperparathyroidism; geriatric patients may show toxicity at serum concentrations ordinarily tolerated by others.

Participants / model
Adults and children 7 and older with bipolar I disorder
Treatment
Lithium carbonate tablets and capsules
Follow-up
Label version effective 16 August 2026
Study design
FDA prescribing information
Funding
not stated in the source

This is the carbonate label. It does not cover lithium orotate, brain aging or supplements.

Read the original source
Chronic low-dose lithium carbonate: thyroid, weight, diabetes and arrhythmia signals; 2026 pilot serious events 29% versus 23%

Randomized controlled trial

Aprahamian I et al. J Clin Psychiatry. 2014;75(7):e672-8. PMID 25093483.

In the 61-person trial followed for 2 years double-blind and 2 more single-blind, renal function by two eGFR equations did not change (P = .453 and .213), but the lithium group gained neutrophils (P = .038), serum TSH (P = .034) and body weight (P = .015), reported more adverse events overall (P = .045), and had a higher incidence of diabetes mellitus (P = .037) and arrhythmia (P = .028); the authors say other adverse events could not be ruled out given the study design. In the 2026 pilot, serious adverse events occurred in 12 of 41 (29%) on lithium versus 9 of 39 (23%) on placebo, none definitely treatment related; increased creatinine was 12 of 41 versus 12 of 39, diarrhea 12 of 41 versus 6 of 39, tiredness 12 of 41 versus 6 of 39, and tremor 10 of 41 versus 6 of 39.

Participants / model
Older adults with MCI
Treatment
Oral lithium carbonate at subtherapeutic serum levels
Follow-up
2 to 4 years
Study design
Randomized trials, safety analyses
Funding
not stated in the source

These are lithium carbonate results. No study found measured these signals for orotate.

Read the original source
Orotate safety: rat NOAEL 400 mg/kg/day (independence unclear), one overdose case, a survey of 211 users

Animal study

Murbach TS et al. Regul Toxicol Pharmacol. 2021;124:104973. PMID 34146638.

In rats given lithium orotate 100, 200 or 400 mg/kg/day for 28 days, no toxicity or target organs were found (NOAEL 400 mg/kg/day), and genotoxicity tests were negative; the paper states that therapeutic lithium doses are 5.5 to 67 times greater than typically recommended supplemental lithium orotate. An 18-year-old who swallowed 18 tablets of an internet lithium orotate supplement (listed as 120 mg lithium orotate each) had a serum lithium of 0.31 then 0.40 mEq/L with nausea, one emesis and mild tremor, and the authors note chronic toxicity is a theoretical concern (Pauze 2007). Among 211 people who took lithium supplements (mostly aspartate 10 mg, with orotate also common), side effects and withdrawal phenomena were reported as more prevalent than the authors expected, in an opportunistic cross-sectional survey (Strawbridge 2025).

Participants / model
Rats; one overdose case; 211 supplement users
Treatment
Oral lithium orotate in rats; supplement tablets; self-reported supplement use
Follow-up
28 days (rats)
Study design
Animal toxicology study, case report and cross-sectional survey
Funding
not stated in the source; the rat paper's abstract gives an AIBMR contact email and no funding or conflict statement

The rat study's independence is not established, because its abstract gives an AIBMR contact email and no funding or conflict statement.

Read the original source
Orotate versus carbonate in rats: 1976 to 1979 papers disagree, and a 2026 commentary doubts the premise

Animal study

Kling MA et al. J Pharm Pharmacol. 1978;30(6):368-70. PMID 26768.

In rats, single injections of 1.0 to 4.0 mEq/kg gave higher serum and brain lithium 8 hours after lithium orotate than after lithium carbonate, with a 24-hour brain level about three times greater (Kling 1978). Smith reported in 1976 that uptake, distribution and excretion of lithium did not differ between orotate, carbonate and chloride after single doses or 20 days of feeding. Smith and Schou repeated the Kling experiment in 1979 and found markedly lower glomerular filtration rate and urine flow after lithium orotate, with the higher lithium concentrations accounted for by the lower kidney function, and advised against using lithium orotate to treat patients. A 2026 commentary argues that no study has shown stable orotate in physiological fluids, that it should be protonated in the stomach and absorbed as Li+, that experimental studies show comparable pharmacokinetics for the two salts, and that focus on one salt could have safety implications (Hajek 2026).

Participants / model
Rats; none in humans
Treatment
Intraperitoneal, subcutaneous, intragastric and dietary lithium salts in rats; an argument paper
Follow-up
Single doses; 20 days of feeding in one study
Study design
Animal pharmacokinetic studies from the 1970s plus a 2026 commentary
Funding
not stated in the source

Rat findings only; none in people.

Read the original source
Orotate in people: a 9-man imaging study, a 1986 uncontrolled report, one case, one registered trial

Human study

Neal MA et al. J Affect Disord. 2024;360:139-145. PMID 38810780.

Nine healthy men took lithium orotate supplements at 5 mg daily for up to 28 days and 7Li-MRI on a 3T scanner detected brain lithium, with two participants showing about 2 to 4 times higher signal; adherence was self-reported, and the abstract does not say whether 5 mg is salt weight or elemental lithium. A 1986 uncontrolled report of 42 alcoholic patients given 150 mg of lithium orotate daily within a multi-component program described minor side effects, and cannot separate lithium orotate from the other treatments. In one Dutch case report a woman taking an internet lithium orotate supplement had a serum lithium below 0.05 mmol/l. The only registered orotate trial found is NCT07459959 (Johns Hopkins University, lithium orotate versus placebo in early Alzheimer disease, estimated 40 participants, phase 1/2, not yet recruiting, listed start 1 December 2026, primary outcomes feasibility, safety and tolerability, no results).

Participants / model
9 healthy men; 42 alcoholic patients; one case report; a registered early Alzheimer disease trial
Treatment
Oral lithium orotate 5 mg or 150 mg daily as stated; an internet supplement
Follow-up
Up to 28 days; not stated in the source for the other reports
Study design
Small imaging study, uncontrolled report, case report and trial registry
Funding
not stated in the source

None of these tests efficacy. The 5 mg and 150 mg figures are as stated in the sources, and the abstract of the 9-man study does not say whether 5 mg is salt weight or elemental lithium.

Read the original source

Why does lithium orotate sit in C tier?

C fits a plausible mechanism and small low-dose lithium carbonate trials, but orotate-specific evidence is limited to mouse data, a 9-person imaging study and case reports. Its claimed advantage over carbonate is disputed, and carbonate-trial safety signals have not been measured for orotate.

Prescription lithium carbonate is FDA-labeled for bipolar disorder, there is a biologically plausible case for low-dose brain protection, and small randomized trials of low-dose lithium carbonate in mild cognitive impairment gave two positive reports from one Brazilian trial and a 2026 US pilot that missed all six coprimary outcomes. A striking 2025 mouse paper covers orotate.

But the evidence for orotate specifically is animal data, a 9-person imaging study and case reports. Its claimed pharmacokinetic advantage is contested by rat work from 1976 and 1979 and by a 2026 commentary, and chronic low-dose lithium carbonate trials report thyroid, weight, diabetes, arrhythmia and tolerability signals that no study found measured for orotate.

The grade covers lithium orotate as sold for brain protection. It is not a grade for prescription lithium carbonate in bipolar disorder.

Lithium carbonate label, version effective 16 August 2026: bipolar I disorder, boxed warning for lithium toxicity

FDA prescribing information

DailyMed, U.S. National Library of Medicine. Lithium carbonate tablets and capsules, prescribing information, label version effective 16 August 2026. Set ID b839ff4b-f62d-41ab-a823-550a756d58ec. openFDA lists NDA 018558 (Hikma) with an original approval status date of 29 January 1982, plus many generic applications.

The label is indicated as monotherapy for bipolar I disorder: acute manic and mixed episodes and maintenance, in patients 7 years and older. It carries a boxed warning for lithium toxicity, saying toxicity tracks serum lithium concentrations and can occur at doses close to therapeutic concentrations. Toxic concentrations (1.5 mEq/L or more) sit close to the therapeutic range (0.8 to 1.2 mEq/L), and above 3 mEq/L patients may progress to seizures, coma and irreversible brain damage. Warnings include diminished renal concentrating ability and nephrogenic diabetes insipidus, hyponatremia, hypothyroidism and hyperthyroidism, and hypercalcemia and hyperparathyroidism; geriatric patients may show toxicity at serum concentrations ordinarily tolerated by others.

Participants / model
Adults and children 7 and older with bipolar I disorder
Treatment
Lithium carbonate tablets and capsules
Follow-up
Label version effective 16 August 2026
Study design
FDA prescribing information
Funding
not stated in the source

This is the carbonate label. It does not cover lithium orotate, brain aging or supplements.

Read the original source
Low-dose lithium in cognitive impairment: 45, 61 and 83 participants; the 2026 pilot met none of 6 coprimary outcomes

Randomized controlled trial

Gildengers AG et al. JAMA Neurol. 2026;83(4):310-319. PMID 41770546.

In 45 people with amnestic mild cognitive impairment (MCI) given lithium to serum concentrations of 0.25 to 0.5 mmol/l or placebo for 12 months, cerebrospinal fluid phosphorylated tau fell (P = 0.03) with better ADAS-cog and attention scores (Forlenza 2011). In 61 people with amnestic MCI given lithium carbonate to subtherapeutic concentrations (0.25 to 0.5 mEq/L) for 2 years, placebo participants declined while lithium participants stayed stable, and CSF amyloid-beta 1-42 rose after 36 months; the declaration of interest was none (Forlenza 2019). In a 2026 US pilot of 83 randomized adults aged 60 or older with MCI (41 lithium carbonate, 42 placebo) on low-dose lithium for 2 years, none of the 6 prespecified coprimary outcomes met the significance threshold; the CVLT-II delayed recall decline was 1.42 points a year on placebo versus 0.73 on lithium (difference 0.69; 95% CI 0.01 to 1.37; P = .05), and hippocampal and cortical volumes declined in both groups (Gildengers 2026). A microdose study of 300 ug once daily for 15 months in people with Alzheimer disease reported MMSE stable on treatment against decline in controls; its abstract gives no sample size or lithium salt (Nunes 2013).

Participants / model
Older adults with amnestic MCI (45, 61 and 83 participants in three reports); patients with Alzheimer disease (sample size not stated in the source)
Treatment
Oral lithium or lithium carbonate at subtherapeutic serum levels; a microdose of an unstated salt
Follow-up
12 months; 2 years; 2 years; 15 months
Study design
Randomized placebo-controlled trials and a small pilot
Funding
not stated in the source; the 2019 report declared no interest

All of these used lithium carbonate or an unstated salt, not orotate. The 2011 and 2019 reports share one registry number, and it is not stated whether the 45 are a subset of the 61.

Read the original source
Chronic low-dose lithium carbonate: thyroid, weight, diabetes and arrhythmia signals; 2026 pilot serious events 29% versus 23%

Randomized controlled trial

Aprahamian I et al. J Clin Psychiatry. 2014;75(7):e672-8. PMID 25093483.

In the 61-person trial followed for 2 years double-blind and 2 more single-blind, renal function by two eGFR equations did not change (P = .453 and .213), but the lithium group gained neutrophils (P = .038), serum TSH (P = .034) and body weight (P = .015), reported more adverse events overall (P = .045), and had a higher incidence of diabetes mellitus (P = .037) and arrhythmia (P = .028); the authors say other adverse events could not be ruled out given the study design. In the 2026 pilot, serious adverse events occurred in 12 of 41 (29%) on lithium versus 9 of 39 (23%) on placebo, none definitely treatment related; increased creatinine was 12 of 41 versus 12 of 39, diarrhea 12 of 41 versus 6 of 39, tiredness 12 of 41 versus 6 of 39, and tremor 10 of 41 versus 6 of 39.

Participants / model
Older adults with MCI
Treatment
Oral lithium carbonate at subtherapeutic serum levels
Follow-up
2 to 4 years
Study design
Randomized trials, safety analyses
Funding
not stated in the source

These are lithium carbonate results. No study found measured these signals for orotate.

Read the original source
Orotate in mice: a 2025 Nature paper and a mouse mania study, with no human efficacy data

Animal study

Aron L et al. Nature. 2025;645(8081):712-721. PMID 40770094.

A Nature paper found that of the metals analyzed, lithium was the only one significantly reduced in the brain in people with MCI, that amyloid sequestration lowered lithium bioavailability further in Alzheimer disease, that cutting cortical lithium by about 50% in mice worsened amyloid and tau pathology and cognition, and that replacement with lithium orotate, described as a salt with reduced amyloid binding, prevented pathological changes and memory loss in Alzheimer mouse models and ageing wild-type mice. In a mouse mania model lithium orotate near-completely blocked amphetamine-induced hyperlocomotion at 1.5 mg/kg while lithium carbonate partly blocked it at 15 and 20 mg/kg, and after 14 days only the carbonate caused polydipsia, raised creatinine in males and raised TSH in females. A 2026 narrative review concludes that the data support a prospective trial of low-dose lithium orotate in MCI and that the repletion hypothesis awaits independent replication.

Participants / model
Mice (Alzheimer models, ageing wild-type, mania model); human brain tissue measurements in MCI
Treatment
Dietary lithium depletion and lithium orotate replacement in mice; lithium orotate or carbonate in the mania model; routes and the orotate dose in the Nature paper are not stated in the source
Follow-up
14 days in the mania model; not stated in the source otherwise
Study design
Animal studies and a narrative review
Funding
No competing interests were declared in the Nature paper; funding is not stated in the source

Mouse findings only. The abstract does not state the orotate dose given to mice, so no mouse-to-human dose conversion is offered.

Read the original source
Orotate versus carbonate in rats: 1976 to 1979 papers disagree, and a 2026 commentary doubts the premise

Animal study

Kling MA et al. J Pharm Pharmacol. 1978;30(6):368-70. PMID 26768.

In rats, single injections of 1.0 to 4.0 mEq/kg gave higher serum and brain lithium 8 hours after lithium orotate than after lithium carbonate, with a 24-hour brain level about three times greater (Kling 1978). Smith reported in 1976 that uptake, distribution and excretion of lithium did not differ between orotate, carbonate and chloride after single doses or 20 days of feeding. Smith and Schou repeated the Kling experiment in 1979 and found markedly lower glomerular filtration rate and urine flow after lithium orotate, with the higher lithium concentrations accounted for by the lower kidney function, and advised against using lithium orotate to treat patients. A 2026 commentary argues that no study has shown stable orotate in physiological fluids, that it should be protonated in the stomach and absorbed as Li+, that experimental studies show comparable pharmacokinetics for the two salts, and that focus on one salt could have safety implications (Hajek 2026).

Participants / model
Rats; none in humans
Treatment
Intraperitoneal, subcutaneous, intragastric and dietary lithium salts in rats; an argument paper
Follow-up
Single doses; 20 days of feeding in one study
Study design
Animal pharmacokinetic studies from the 1970s plus a 2026 commentary
Funding
not stated in the source

Rat findings only; none in people.

Read the original source
Orotate in people: a 9-man imaging study, a 1986 uncontrolled report, one case, one registered trial

Human study

Neal MA et al. J Affect Disord. 2024;360:139-145. PMID 38810780.

Nine healthy men took lithium orotate supplements at 5 mg daily for up to 28 days and 7Li-MRI on a 3T scanner detected brain lithium, with two participants showing about 2 to 4 times higher signal; adherence was self-reported, and the abstract does not say whether 5 mg is salt weight or elemental lithium. A 1986 uncontrolled report of 42 alcoholic patients given 150 mg of lithium orotate daily within a multi-component program described minor side effects, and cannot separate lithium orotate from the other treatments. In one Dutch case report a woman taking an internet lithium orotate supplement had a serum lithium below 0.05 mmol/l. The only registered orotate trial found is NCT07459959 (Johns Hopkins University, lithium orotate versus placebo in early Alzheimer disease, estimated 40 participants, phase 1/2, not yet recruiting, listed start 1 December 2026, primary outcomes feasibility, safety and tolerability, no results).

Participants / model
9 healthy men; 42 alcoholic patients; one case report; a registered early Alzheimer disease trial
Treatment
Oral lithium orotate 5 mg or 150 mg daily as stated; an internet supplement
Follow-up
Up to 28 days; not stated in the source for the other reports
Study design
Small imaging study, uncontrolled report, case report and trial registry
Funding
not stated in the source

None of these tests efficacy. The 5 mg and 150 mg figures are as stated in the sources, and the abstract of the 9-man study does not say whether 5 mg is salt weight or elemental lithium.

Read the original source
PubMed search, 11 October 2026: 22 records, no randomized trial of orotate in people

PubMed search record

PubMed search run on 11 October 2026: "lithium orotate". 22 records returned. ClinicalTrials.gov search for "lithium orotate" run the same day.

The search returned 22 records, and all 22 titles were reviewed. They were reviews and commentaries, rat pharmacokinetic and toxicology studies, two mouse studies, two case reports and a letter, one survey and one qualitative study, one human imaging study, two older clinical reports (Sartori 1986 and a 1973 report titled as a two-year study of clinical applications, title only reviewed) and several records only tangentially about lithium. None was a randomized controlled trial of lithium orotate in people. A ClinicalTrials.gov search for lithium orotate returned 1 study (NCT07459959). All randomized human evidence for low-dose lithium in cognitive impairment found in this review used lithium carbonate or an unstated salt.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 11 October 2026
Study design
Literature search and trial registry
Funding
not stated in the source

A search result shows what PubMed returned on that date. It is not proof that no unindexed study exists.

Read the original source

Studies and sources

PubChem: lithium orotate versus lithium carbonate; salt weight is not elemental lithium

Chemical identity record

National Library of Medicine. PubChem compound records CID 23686432 (lithium orotate) and CID 11125 (lithium carbonate). openFDA Drugs@FDA and DailyMed drug-name searches for lithium orotate run on 11 October 2026. The elemental-lithium figures come from a toxicology case report (Pauze 2007, PMID 18072162), and the supplement survey is Strawbridge 2025 (PMID 40152059).

Lithium orotate: PubChem CID 23686432, C5H3LiN2O4, 162.1 g/mol, CAS 5266-20-6. Lithium carbonate, the salt in prescription lithium: CID 11125, CLi2O3, 73.9 g/mol, CAS 554-13-2. The salt weight and the lithium weight differ a lot: a toxicology case report gives 3.83 mg of elemental lithium per 100 mg of lithium orotate versus 18.8 mg per 100 mg of lithium carbonate, so a label dose written as 5 mg or 120 mg needs to say whether it is salt or elemental lithium. Lithium supplements are also sold as other salts: in a survey of 211 supplement users the most common form was aspartate at 10 mg once a day. On 11 October 2026 an openFDA Drugs@FDA query for lithium orotate returned no match and a DailyMed drug-name search returned no labels.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined salts; supplement product forms vary
Follow-up
Searches run on 11 October 2026
Study design
NLM chemical records plus dated US approval-record search
Funding
not stated in the source

Identity records and a search only; they say nothing about efficacy or safety. Whether common retail orotate products list salt weight or elemental lithium is not established here, and the US dietary-supplement status of lithium orotate is not established here.

Read the original source
Lithium carbonate label, version effective 16 August 2026: bipolar I disorder, boxed warning for lithium toxicity

FDA prescribing information

DailyMed, U.S. National Library of Medicine. Lithium carbonate tablets and capsules, prescribing information, label version effective 16 August 2026. Set ID b839ff4b-f62d-41ab-a823-550a756d58ec. openFDA lists NDA 018558 (Hikma) with an original approval status date of 29 January 1982, plus many generic applications.

The label is indicated as monotherapy for bipolar I disorder: acute manic and mixed episodes and maintenance, in patients 7 years and older. It carries a boxed warning for lithium toxicity, saying toxicity tracks serum lithium concentrations and can occur at doses close to therapeutic concentrations. Toxic concentrations (1.5 mEq/L or more) sit close to the therapeutic range (0.8 to 1.2 mEq/L), and above 3 mEq/L patients may progress to seizures, coma and irreversible brain damage. Warnings include diminished renal concentrating ability and nephrogenic diabetes insipidus, hyponatremia, hypothyroidism and hyperthyroidism, and hypercalcemia and hyperparathyroidism; geriatric patients may show toxicity at serum concentrations ordinarily tolerated by others.

Participants / model
Adults and children 7 and older with bipolar I disorder
Treatment
Lithium carbonate tablets and capsules
Follow-up
Label version effective 16 August 2026
Study design
FDA prescribing information
Funding
not stated in the source

This is the carbonate label. It does not cover lithium orotate, brain aging or supplements.

Read the original source
Drinking-water lithium: Danish (73 731 cases) and Scottish (37 597 people) studies, mixed

Human study

Kessing LV et al. JAMA Psychiatry. 2017;74(10):1005-1010. PMID 28832877.

A Danish nationwide nested case-control study of 73 731 people with dementia and 733 653 controls found a nonlinear link: compared with 2.0 to 5.0 ug/L lithium in drinking water, the dementia incidence rate ratio was 0.83 (95% CI 0.81 to 0.85) above 15.0 ug/L, 0.98 (0.96 to 1.01) at 10.1 to 15.0 ug/L, and 1.22 (1.19 to 1.25) at 5.1 to 10.0 ug/L, and the authors say confounding by municipality cannot be excluded. A Scottish cohort of 37 597 people with a mean water lithium of 1.45 ug/L did not support a protective association and found a trend to higher dementia risk in women at levels below 2.1 ug/L (HR 1.17, 95% CI 1.04 to 1.32 in the second quartile).

Participants / model
Danish and Scottish general populations
Treatment
Environmental lithium in drinking water
Follow-up
not stated in the source
Study design
Observational nested case-control study and cohort study
Funding
not stated in the source

Drinking-water lithium is not an orotate supplement dose.

Read the original source
Low-dose lithium in cognitive impairment: 45, 61 and 83 participants; the 2026 pilot met none of 6 coprimary outcomes

Randomized controlled trial

Gildengers AG et al. JAMA Neurol. 2026;83(4):310-319. PMID 41770546.

In 45 people with amnestic mild cognitive impairment (MCI) given lithium to serum concentrations of 0.25 to 0.5 mmol/l or placebo for 12 months, cerebrospinal fluid phosphorylated tau fell (P = 0.03) with better ADAS-cog and attention scores (Forlenza 2011). In 61 people with amnestic MCI given lithium carbonate to subtherapeutic concentrations (0.25 to 0.5 mEq/L) for 2 years, placebo participants declined while lithium participants stayed stable, and CSF amyloid-beta 1-42 rose after 36 months; the declaration of interest was none (Forlenza 2019). In a 2026 US pilot of 83 randomized adults aged 60 or older with MCI (41 lithium carbonate, 42 placebo) on low-dose lithium for 2 years, none of the 6 prespecified coprimary outcomes met the significance threshold; the CVLT-II delayed recall decline was 1.42 points a year on placebo versus 0.73 on lithium (difference 0.69; 95% CI 0.01 to 1.37; P = .05), and hippocampal and cortical volumes declined in both groups (Gildengers 2026). A microdose study of 300 ug once daily for 15 months in people with Alzheimer disease reported MMSE stable on treatment against decline in controls; its abstract gives no sample size or lithium salt (Nunes 2013).

Participants / model
Older adults with amnestic MCI (45, 61 and 83 participants in three reports); patients with Alzheimer disease (sample size not stated in the source)
Treatment
Oral lithium or lithium carbonate at subtherapeutic serum levels; a microdose of an unstated salt
Follow-up
12 months; 2 years; 2 years; 15 months
Study design
Randomized placebo-controlled trials and a small pilot
Funding
not stated in the source; the 2019 report declared no interest

All of these used lithium carbonate or an unstated salt, not orotate. The 2011 and 2019 reports share one registry number, and it is not stated whether the 45 are a subset of the 61.

Read the original source
Chronic low-dose lithium carbonate: thyroid, weight, diabetes and arrhythmia signals; 2026 pilot serious events 29% versus 23%

Randomized controlled trial

Aprahamian I et al. J Clin Psychiatry. 2014;75(7):e672-8. PMID 25093483.

In the 61-person trial followed for 2 years double-blind and 2 more single-blind, renal function by two eGFR equations did not change (P = .453 and .213), but the lithium group gained neutrophils (P = .038), serum TSH (P = .034) and body weight (P = .015), reported more adverse events overall (P = .045), and had a higher incidence of diabetes mellitus (P = .037) and arrhythmia (P = .028); the authors say other adverse events could not be ruled out given the study design. In the 2026 pilot, serious adverse events occurred in 12 of 41 (29%) on lithium versus 9 of 39 (23%) on placebo, none definitely treatment related; increased creatinine was 12 of 41 versus 12 of 39, diarrhea 12 of 41 versus 6 of 39, tiredness 12 of 41 versus 6 of 39, and tremor 10 of 41 versus 6 of 39.

Participants / model
Older adults with MCI
Treatment
Oral lithium carbonate at subtherapeutic serum levels
Follow-up
2 to 4 years
Study design
Randomized trials, safety analyses
Funding
not stated in the source

These are lithium carbonate results. No study found measured these signals for orotate.

Read the original source
Orotate in mice: a 2025 Nature paper and a mouse mania study, with no human efficacy data

Animal study

Aron L et al. Nature. 2025;645(8081):712-721. PMID 40770094.

A Nature paper found that of the metals analyzed, lithium was the only one significantly reduced in the brain in people with MCI, that amyloid sequestration lowered lithium bioavailability further in Alzheimer disease, that cutting cortical lithium by about 50% in mice worsened amyloid and tau pathology and cognition, and that replacement with lithium orotate, described as a salt with reduced amyloid binding, prevented pathological changes and memory loss in Alzheimer mouse models and ageing wild-type mice. In a mouse mania model lithium orotate near-completely blocked amphetamine-induced hyperlocomotion at 1.5 mg/kg while lithium carbonate partly blocked it at 15 and 20 mg/kg, and after 14 days only the carbonate caused polydipsia, raised creatinine in males and raised TSH in females. A 2026 narrative review concludes that the data support a prospective trial of low-dose lithium orotate in MCI and that the repletion hypothesis awaits independent replication.

Participants / model
Mice (Alzheimer models, ageing wild-type, mania model); human brain tissue measurements in MCI
Treatment
Dietary lithium depletion and lithium orotate replacement in mice; lithium orotate or carbonate in the mania model; routes and the orotate dose in the Nature paper are not stated in the source
Follow-up
14 days in the mania model; not stated in the source otherwise
Study design
Animal studies and a narrative review
Funding
No competing interests were declared in the Nature paper; funding is not stated in the source

Mouse findings only. The abstract does not state the orotate dose given to mice, so no mouse-to-human dose conversion is offered.

Read the original source
Orotate versus carbonate in rats: 1976 to 1979 papers disagree, and a 2026 commentary doubts the premise

Animal study

Kling MA et al. J Pharm Pharmacol. 1978;30(6):368-70. PMID 26768.

In rats, single injections of 1.0 to 4.0 mEq/kg gave higher serum and brain lithium 8 hours after lithium orotate than after lithium carbonate, with a 24-hour brain level about three times greater (Kling 1978). Smith reported in 1976 that uptake, distribution and excretion of lithium did not differ between orotate, carbonate and chloride after single doses or 20 days of feeding. Smith and Schou repeated the Kling experiment in 1979 and found markedly lower glomerular filtration rate and urine flow after lithium orotate, with the higher lithium concentrations accounted for by the lower kidney function, and advised against using lithium orotate to treat patients. A 2026 commentary argues that no study has shown stable orotate in physiological fluids, that it should be protonated in the stomach and absorbed as Li+, that experimental studies show comparable pharmacokinetics for the two salts, and that focus on one salt could have safety implications (Hajek 2026).

Participants / model
Rats; none in humans
Treatment
Intraperitoneal, subcutaneous, intragastric and dietary lithium salts in rats; an argument paper
Follow-up
Single doses; 20 days of feeding in one study
Study design
Animal pharmacokinetic studies from the 1970s plus a 2026 commentary
Funding
not stated in the source

Rat findings only; none in people.

Read the original source
Orotate in people: a 9-man imaging study, a 1986 uncontrolled report, one case, one registered trial

Human study

Neal MA et al. J Affect Disord. 2024;360:139-145. PMID 38810780.

Nine healthy men took lithium orotate supplements at 5 mg daily for up to 28 days and 7Li-MRI on a 3T scanner detected brain lithium, with two participants showing about 2 to 4 times higher signal; adherence was self-reported, and the abstract does not say whether 5 mg is salt weight or elemental lithium. A 1986 uncontrolled report of 42 alcoholic patients given 150 mg of lithium orotate daily within a multi-component program described minor side effects, and cannot separate lithium orotate from the other treatments. In one Dutch case report a woman taking an internet lithium orotate supplement had a serum lithium below 0.05 mmol/l. The only registered orotate trial found is NCT07459959 (Johns Hopkins University, lithium orotate versus placebo in early Alzheimer disease, estimated 40 participants, phase 1/2, not yet recruiting, listed start 1 December 2026, primary outcomes feasibility, safety and tolerability, no results).

Participants / model
9 healthy men; 42 alcoholic patients; one case report; a registered early Alzheimer disease trial
Treatment
Oral lithium orotate 5 mg or 150 mg daily as stated; an internet supplement
Follow-up
Up to 28 days; not stated in the source for the other reports
Study design
Small imaging study, uncontrolled report, case report and trial registry
Funding
not stated in the source

None of these tests efficacy. The 5 mg and 150 mg figures are as stated in the sources, and the abstract of the 9-man study does not say whether 5 mg is salt weight or elemental lithium.

Read the original source
Orotate safety: rat NOAEL 400 mg/kg/day (independence unclear), one overdose case, a survey of 211 users

Animal study

Murbach TS et al. Regul Toxicol Pharmacol. 2021;124:104973. PMID 34146638.

In rats given lithium orotate 100, 200 or 400 mg/kg/day for 28 days, no toxicity or target organs were found (NOAEL 400 mg/kg/day), and genotoxicity tests were negative; the paper states that therapeutic lithium doses are 5.5 to 67 times greater than typically recommended supplemental lithium orotate. An 18-year-old who swallowed 18 tablets of an internet lithium orotate supplement (listed as 120 mg lithium orotate each) had a serum lithium of 0.31 then 0.40 mEq/L with nausea, one emesis and mild tremor, and the authors note chronic toxicity is a theoretical concern (Pauze 2007). Among 211 people who took lithium supplements (mostly aspartate 10 mg, with orotate also common), side effects and withdrawal phenomena were reported as more prevalent than the authors expected, in an opportunistic cross-sectional survey (Strawbridge 2025).

Participants / model
Rats; one overdose case; 211 supplement users
Treatment
Oral lithium orotate in rats; supplement tablets; self-reported supplement use
Follow-up
28 days (rats)
Study design
Animal toxicology study, case report and cross-sectional survey
Funding
not stated in the source; the rat paper's abstract gives an AIBMR contact email and no funding or conflict statement

The rat study's independence is not established, because its abstract gives an AIBMR contact email and no funding or conflict statement.

Read the original source

Why is Lithium orotate in C tier?

C fits a lithium salt with a plausible mechanism and small positive and null trials of low-dose lithium carbonate, but orotate-specific evidence limited to mouse data, a 9-person imaging study and case reports. Its claimed pharmacokinetic advantage over carbonate is disputed, and chronic low-dose carbonate trials report thyroid, weight, diabetes, arrhythmia and tolerability signals that no study found measured for orotate. The grade covers lithium orotate as sold for brain protection, not prescription lithium carbonate.